Introduction
Excess secretion or administration of glucocorticoids leads to hyperglycemia, hyperinsulinemia and insulin resistance [1] . Glucocorticoids decrease the rate of basal and insulinstimulated glucose uptake in skeletal muscle [2] . Glucocorticoid-induced insulin resistance is related to deficiency in post-receptor insulin activity [3] . Deleterious effect and cellular mechanisms of the glucocorticoid therapy are well-known [4] . Glucocorticoid therapy leads to cell apoptosis, inhibits osteoblast genesis and bone formation which can lead to low bone turnover state [5, 6] . Glutamate dehydrogenase (GDH) is a mitochondrial enzyme enzyme controlling the oxidation of glutamate [6] . The GDH serves as a link among anabolic and catabolic pathways which catalyzes the reversible oxidative deamination of glutamate to α-ketoglutarate [7] .
The GDH has a key role in insulin secretion from pancreatic beta cells in response to glutamine [8] . Overexpression of the GDH increases insulin secretion through glutamine stimulation [9] . Based on the animal studies, insulin secretion at low glucose is not mediated by GDH overexpression whereas high glucosestimulated insulin secretion is influenced by GDH overexpression [10] . Also, Rehman et al.
identified that dexamethasone treatment alters insulin, leptin, and adiponectin levels in male mice [11] . Overexpression of the GDH modifies insulin secretion in pancreatic islets [12] . Additionally, diabetes is one of the main endocrine diseases and interacts with several hormones such as glucocorticoids which presumably lead to insulin resistance [10] . The GDH controls the insulin secretion in the pancreatic beta cells and inhibition of the GDH activity decreases insulin release and glutamate concentrations [9] while activation of the GDH is associated with hyperinsulinemia [10] .
Therefore, the aim of the current study was to determine the GDH activity in mice exposed to dexamethasone. 
Materials and Methods

Animals
Faculty of Pharmacy, Shahid Sadughi
University of Medical Sciences, Yazd, Iran.
Experimental protocol
Group 1 was kept as control (received normal saline and standard pellet). Group 2 was fed with standard chew pellet and 1mg/kg per day of dexamethasone. Group 3 received standard diet and was injected with dexamethasone (3 mg/kg per day). Group 4 was fed with standard diet + 5 mg/kg dexamethasone per day. After 21 days, rats were euthanized with an overdose injection of pentobarbital (300 mg/kg, i.p.), pancreas was obtained and GDH, insulin and serum glucose levels were determined [13] .
Biochemical activity
The GDH activity was determined using 
Results
The results of the dexamethasone on serum insulin, glucose and GDH activity in mice is 
Discussion
Diabetes is one of the prominent endocrine disorders in the world with deranged metabolism and energy expenditure [13] .
Insulin resistance is the conditions such as diabetes, obesity and dyslipidemia [14] . Excess administration of glucocorticoids causes hyperglycemia and hyperinsulinemia with insulin resistance [15] . Glutamate is the main product of glutamate dehydrogenase activity that can help insulin secretion. Despite previous studies conducted on the role of glutamate on dexamethasone-induced diabetes, there is scarce information regarding role of the dexamethasone on pancreatic GDH, insulin and serum glucose in the mice exposed to dexamethasone. So, the novelty of the current study was to determine GDH activity in mice exposed to dexamethasone. Based on the findings of the current study, dexamethasone significantly increased serum glucose levels compared to the begining of the study. Also, dexamethasone dose dependently increased glutamate dehydrogenase activity and insulin levels in dexamethasone treated rat.
The dexamethasone-induced increase in the serum insulin and glucose indicates that insulin resistance is observed by rosiglitazone administration [16] . Glucocorticoids administration inhibits pancreatic insulin secretion, reduces glucose utilization and increases glucagon secretion [13] . Glucose stimulation of insulin release was associated with suppression of flux through the GDH in normal and transgenic mouse pancreatic islets. Glucose stimulation of the insulin release was related to GDH, consistent with the well-known allosteric inhibitory effect of the GTP and ATP on activity of the enzyme [17] . Glucocorticoids decrease glucose utilization in muscles by modulating the insulin receptor [13, 18] .
Dexamethasone has diabetogenic effects by dysregulation of glucose expenditure in liver, muscles and adipose tissue [19] . Reduction in peripheral insulin sensitivity may be compensated by the intensified pancreatic βcells function, but, as the latter is also directly affected by glucocorticoids, over time decompensation arises. Administration of glutamine partially prevents glucocorticoidsinduced muscle atrophy. Glutamine blocks glucocorticoids induction of myostatin mRNA and protein expression [20] . Despite direct mechanism(s) for how the GDH and dexamethasone impress cellular mechanism on insulin release is not fully elicited, but the oxidative deamination of glutamate by GDH stimulates insulin release in the beta cell mitochondria [21] . Oxidative deamination of glutamate increase the mitochondrial αketoglutarate, raises the NADH/NAD and NADPH/NADP ratios [22] .
The GDH regulates insulin secretion by its role 
Conclusion
These results suggest that dexamethasone increases glucose which leads to elevating GDH activity and then then increasing insulin.
However, insulin was not enough to normalize glucose levels and led to hyperglycemia.
Therefore, it is suggested to reduce dexamethasone administration.
However there was no similar study to compare the results. Further research is needed to determine the accuracy of the results. Also, cellular and molecular studies are required to determine cellular mechanism(s) for the obtained results.
